Tuesday, January 31, 2017 10:05:12 PM
http://analysis.secfilings.com/articles/148-axim-biotech-building-a-lower-cost-portfolio-of-cannabinoid-therapeutics
OWCP will use the same playbook for all FDA approved cremes, and then for illnesses treated with the sublingual tablet.
As I've said before, I'm positive top MBA programs this year will do a case study comparison of the traditional GWPH route vs the new OWCP/AXIM route.
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM